ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
34.65
0.00%
US Tech 100
19,193.20
0.13%
S&P 500
5,431.60
-0.04%
US Dollar vs CAD
1.37407
0.04%
Bitcoin
65,889.83
-1.12%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Keros Therapeutics Inc (KROS)

  7. Keros Therapeutics Inc (KROS) News

KROS

Keros Therapeutics (KROS)

Keros Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KROS
DateTimeSourceHeadlineSymbolCompany
06/17/20245:07AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
06/17/20245:00AMGlobeNewswire Inc.Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology AssociationNASDAQ:KROSKeros Therapeutics Inc
06/04/20247:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
06/04/20247:00AMGlobeNewswire Inc.Keros Therapeutics to Host a Corporate Update Conference Call and WebcastNASDAQ:KROSKeros Therapeutics Inc
06/03/20243:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
06/03/20243:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
06/03/20243:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
06/03/20247:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
06/03/20247:00AMGlobeNewswire Inc.Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:KROSKeros Therapeutics Inc
05/30/20243:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
05/28/20243:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
05/28/20243:01PMGlobeNewswire Inc.Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of DirectorsNASDAQ:KROSKeros Therapeutics Inc
05/14/20249:00AMGlobeNewswire Inc.Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology AssociationNASDAQ:KROSKeros Therapeutics Inc
05/08/20247:03AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KROSKeros Therapeutics Inc
05/08/20247:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
05/08/20247:00AMGlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
03/14/20247:00AMGlobeNewswire Inc.Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic SyndromesNASDAQ:KROSKeros Therapeutics Inc
03/06/20247:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
03/05/20247:02AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
03/05/20247:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
03/05/20247:00AMGlobeNewswire Inc.Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma ConferenceNASDAQ:KROSKeros Therapeutics Inc
02/28/20243:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
02/28/20243:01PMGlobeNewswire Inc.Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:KROSKeros Therapeutics Inc
02/23/20244:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
02/15/20247:41PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
02/15/20247:40PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
02/15/20247:38PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
02/15/20247:37PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KROSKeros Therapeutics Inc
01/29/20247:00AMGlobeNewswire Inc.Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual CongressNASDAQ:KROSKeros Therapeutics Inc
01/09/20247:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:KROSKeros Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KROS

Your Recent History

USOTC
CNNA
Cann American (CE)
USOTC
ERHE
ERHC Energy (CE)
USOTC
HHSE
Hannover House (PK)
USOTC
SNPW
Sun Pacific (PK)
USOTC
VXIT
Virexit Technologies (PK)
USOTC
RNVA
Rennova Health (PK)
USOTC
RONN
Ronn Motor (PK)
USOTC
DBMM
Digital Brand Media and ... (PK)
USOTC
ELTP
Elite Pharmaceuticals (QB)
NASDAQ
COOP
Mr Cooper
NASDAQ
AVXL
Anavex Life Sciences
USOTC
CIVX
CTR Investments and Cons... (PK)
USOTC
FNMA
Fannie Mae (QB)
USOTC
NWBO
Northwest Biotherapeutics (QB)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
SMCE
SMC Entertainment (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved